24/7 Market News Snapshot 19 March, 2025 – Virpax Pharmaceuticals, Inc. Common Stock (NASDAQ:VRPX)
DENVER, Colo., 19 March, 2025 (247marketnews.com) – (Nasdaq:VRPX) are discussed in this article.
Virpax Pharmaceuticals, Inc. (Nasdaq:VRPX) is experiencing notable activity in the market, trading at $0.133, reflecting a 2.31% uptick from the previous closing price of $0.130 in pre-market sessions. With a substantial trading volume of approximately 43.92 million shares, the heightened investor interest signals potential volatility and positive sentiment surrounding the company. This recent momentum suggests a favorable short-term outlook for Virpax, particularly if sustained buying pressure continues to drive market interest.
In a strategic development, Virpax has announced a 1-for-25 reverse stock split, set to take effect at 12:01 a.m. Eastern Time on March 20, 2025. This move comes after a special stockholder meeting led to Board approval, reflecting the company’s commitment to enhance its market position. Following the reverse split, outstanding shares will decrease from roughly 31,062,581 to an estimated 1,242,504 shares, while shareholder ownership will remain proportionate, barring adjustments for fractional shares.
The reverse stock split is primarily aimed at ensuring compliance with Nasdaq’s minimum bid price requirement of $1.00 per share, also intended to attract institutional and retail investors to Virpax’s stock. The company’s shares will continue to trade under the symbol “VRPX,” with split-adjusted trading commencing March 21, 2025.
Virpax is committed to developing innovative non-addictive pain management solutions and advancing drug candidates, including Probudur™, Envelta™, and NobrXiol™, which target a range of therapeutic areas, including post-operative pain relief and rare pediatric epilepsy. This strategic financial initiative, coupled with the promising market activity, positions Virpax to enhance its presence and partnerships within the pharmaceutical industry.